Fennec Pharmaceuticals Inc. (TSE:FRX – Get Free Report) Director Rostislav Christov Raykov sold 7,569 shares of the company’s stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of C$9.71, for a total transaction of C$73,503.54.
Rostislav Christov Raykov also recently made the following trade(s):
- On Wednesday, February 5th, Rostislav Christov Raykov sold 2,431 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of C$9.66, for a total transaction of C$23,476.17.
- On Monday, January 6th, Rostislav Christov Raykov sold 10,000 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of C$8.76, for a total transaction of C$87,552.00.
- On Friday, December 20th, Rostislav Christov Raykov purchased 25,000 shares of Fennec Pharmaceuticals stock. The shares were acquired at an average price of C$3.87 per share, for a total transaction of C$96,840.00.
Fennec Pharmaceuticals Price Performance
TSE FRX traded down C$0.26 on Thursday, hitting C$9.43. 178 shares of the company were exchanged, compared to its average volume of 1,596. The company has a current ratio of 7.80, a quick ratio of 10.17 and a debt-to-equity ratio of -620.83. The company has a market cap of C$181.85 million, a P/E ratio of -159.74 and a beta of 0.25. Fennec Pharmaceuticals Inc. has a 1-year low of C$5.65 and a 1-year high of C$15.20. The firm has a 50 day moving average of C$9.16 and a two-hundred day moving average of C$7.86.
Wall Street Analysts Forecast Growth
Get Our Latest Report on Fennec Pharmaceuticals
Fennec Pharmaceuticals Company Profile
Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.
Read More
- Five stocks we like better than Fennec Pharmaceuticals
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Super Micro Computer Is Now NASDAQ Compliant—But Is It a Buy?
- What is the Dogs of the Dow Strategy? Overview and Examples
- Taiwan Semi’s $100 Billion Investment: Fate of the Chipmakers
- What Are Treasury Bonds?
- 3 Stocks Primed for Compounding Wealth This Decade
Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
